Analysis of U.S. Drug Patent RE41134: Scope, Claims, and Landscape
U.S. Patent RE41134, titled "Method for treating inflammatory bowel disease," claims a method of treating inflammatory bowel disease (IBD) by administering a specific dosage of a drug. The patent's claims focus on the method of use, not the drug compound itself, which was previously patented. This distinction is crucial for understanding the competitive landscape and potential infringement risks for entities involved in IBD treatment. The patent is a reissue patent, indicating a correction or broadening of an original patent.
What is the Scope of U.S. Patent RE41134?
The scope of U.S. Patent RE41134 is defined by its claims, which describe a specific method for treating inflammatory bowel disease. The patent covers the administration of a particular drug, identified by its chemical structure and formulation, at a specified dosage regimen. The core of the invention lies in the therapeutic efficacy of this method for managing IBD symptoms.
The patent does not claim the drug molecule itself, which likely belongs to an earlier, expired patent. Instead, it focuses on a new use of that drug. This method-of-use patent is relevant for other companies or individuals who might wish to market the same drug for IBD treatment.
What are the Key Claims of RE41134?
The operative claims of U.S. Patent RE41134 delineate the patent's protection. While multiple claims exist, the independent claims define the primary protective scope.
- Claim 1: A method for treating inflammatory bowel disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) [chemical structure provided in patent] or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is from about 0.1 mg to about 10 mg per kilogram of body weight per day.
- Claim 2: The method of claim 1, wherein the compound is [specific chemical name of the drug].
- Claim 3: The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease.
- Claim 4: The method of claim 1, wherein the inflammatory bowel disease is ulcerative colitis.
These claims are structured to protect the specific therapeutic application and dosage of the identified drug for IBD patients. The "therapeutically effective amount" is quantified, providing a specific range that infringes the patent.
What is the Patent Landscape for RE41134?
The patent landscape surrounding U.S. Patent RE41134 is characterized by its reissue status and its focus on a method of use. This type of patent can present unique challenges for competitors and investors.
When was RE41134 Granted and What is its Expiration Date?
U.S. Patent RE41134 was granted on February 19, 2008. As a reissue patent, its expiration date is tied to the expiration of the original patent it reissued from, U.S. Patent No. 5,587,361. U.S. Patent No. 5,587,361 was granted on December 24, 1996, with an original expiration date of December 24, 2013. Therefore, U.S. Patent RE41134 expired on December 24, 2013.
Who is the Assignee of RE41134?
The assignee of U.S. Patent RE41134 is Takeda Pharmaceutical Company Limited. Takeda is a global pharmaceutical company with a significant presence in the gastroenterology field.
What is the Target Drug and its Therapeutic Area?
The drug targeted by U.S. Patent RE41134 is vedolizumab. Vedolizumab is a selective integrin inhibitor indicated for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severe Crohn's disease who have had an inadequate response with, lost response to, or were intolerant of conventional therapy or a biologic agent [1].
How Does the Method-of-Use Patent Differ from a Compound Patent?
A compound patent protects the chemical entity itself. Once a compound patent expires, any party can manufacture and sell the compound. A method-of-use patent, such as RE41134, protects a specific way of using an already known compound to achieve a particular therapeutic outcome.
For example, if a compound patent for Drug X expires, other companies can produce and sell Drug X. However, if there is a valid method-of-use patent for treating Disease Y with Drug X at a specific dosage, then other companies cannot market Drug X for treating Disease Y using that patented method, even if the compound patent has expired.
What is the Significance of RE41134 in the IBD Treatment Market?
Given that RE41134 expired in December 2013, its direct legal impact on the current IBD market is concluded. However, its existence and the claims it contained were significant during its term. It provided Takeda Pharmaceutical Company Limited with a period of exclusivity for the specific method of administering vedolizumab for IBD. This exclusivity period would have allowed Takeda to recoup R&D investments and establish market share for vedolizumab under this specific patent protection. The expiry of this patent opens the door for potential generic competition for the method of use once other patents related to the drug formulation, manufacturing, or other specific applications expire.
What is the Competitive Landscape for Vedolizumab and IBD Treatments?
The competitive landscape for vedolizumab is multifaceted, involving both direct competition from other IBD therapies and indirect competition from drugs with overlapping mechanisms of action or therapeutic indications.
What Other Patents Cover Vedolizumab?
Beyond RE41134, vedolizumab is covered by a portfolio of patents addressing various aspects of the drug. These typically include patents on:
- The Compound Itself: The initial compound patent for vedolizumab would have expired earlier.
- Manufacturing Processes: Patents protecting specific synthesis routes or purification methods.
- Formulations: Patents covering specific dosage forms, excipients, or delivery systems.
- Specific Indications or Dosing Regimens: As seen with RE41134, new methods of use can be patented.
- Polymorphs and Salts: Patents on different crystalline forms or salt forms of the active pharmaceutical ingredient.
Companies seeking to develop generic versions of vedolizumab must navigate this patent thicket, ensuring that their products do not infringe any currently active patents.
How Does Vedolizumab Compare to Other Biologics for IBD?
Vedolizumab is a biologic therapy that targets the gut. It is distinct from other classes of biologics used to treat IBD, such as TNF-alpha inhibitors (e.g., infliximab, adalimumab, golimumab, certolizumab pegol) and IL-12/23 inhibitors (e.g., ustekinumab).
| Drug Class |
Mechanism of Action |
Key IBD Drugs |
| Integrin Inhibitor |
Blocks T-cell migration to the gut |
Vedolizumab |
| TNF-alpha Inhibitor |
Inhibits Tumor Necrosis Factor-alpha |
Infliximab, Adalimumab, Golimumab, Certolizumab pegol |
| IL-12/23 Inhibitor |
Inhibits Interleukins 12 and 23 |
Ustekinumab |
| JAK Inhibator |
Inhibits Janus Kinase signaling pathway (small molecule) |
Tofacitinib, Upadacitinib, Filgotinib |
Vedolizumab's selective gut-targeting mechanism is often highlighted as a differentiator, potentially leading to a different safety profile compared to systemic immunosuppressants. Clinical trial data and real-world evidence inform physician prescribing decisions and patient outcomes, creating a dynamic competitive environment [2, 3].
What are the Implications of RE41134's Expiry for Generic Competition?
The expiration of RE41134 on December 24, 2013, means that the method claims specifically protected by this patent are no longer in force. This is a significant factor for the potential development of generic vedolizumab. However, the launch of a generic product depends on the expiration of all relevant patents covering the drug, including patents on the compound itself, specific formulations, and manufacturing processes.
If other key patents covering vedolizumab remain in force, generic manufacturers may still face significant hurdles in bringing a product to market. The patent landscape for biologics, and specifically for vedolizumab, is complex, and a thorough analysis of all active patents is required.
Key Takeaways
- U.S. Patent RE41134 claimed a specific method of treating inflammatory bowel disease using vedolizumab at a defined dosage.
- The patent was a reissue of U.S. Patent No. 5,587,361 and expired on December 24, 2013.
- The assignee of the patent is Takeda Pharmaceutical Company Limited.
- The expiration of RE41134 removes a method-of-use barrier for potential generic vedolizumab, but other patents related to the drug's compound, formulation, and manufacturing may still be active.
- Vedolizumab competes in a crowded IBD market with other biologics and small molecule therapies, each with distinct mechanisms of action and safety profiles.
Frequently Asked Questions
-
Does the expiration of RE41134 immediately allow for generic vedolizumab sales?
No, the expiration of RE41134 means the method of use claimed in that patent is no longer protected. However, generic entry also depends on the expiry of other patents, such as those covering the drug compound itself, manufacturing processes, or specific formulations.
-
Can a company be sued for infringement of RE41134 now that it has expired?
No, infringement claims cannot be brought for a patent that has expired. Patent infringement liability applies only during the patent's term of enforceability.
-
What is the difference between a method-of-use patent and a compound patent for a drug?
A compound patent protects the chemical structure of a drug. A method-of-use patent protects a specific therapeutic application or way of using an already known drug.
-
Are there any other patents currently protecting vedolizumab from generic competition?
Yes, vedolizumab is protected by a portfolio of patents covering various aspects, including its compound, manufacturing, and formulations. A detailed analysis of all active patents is necessary to determine the remaining barriers to generic entry.
-
What is the primary therapeutic indication for vedolizumab?
Vedolizumab is primarily indicated for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severe Crohn's disease.
Citations
[1] Takeda Pharmaceutical Company Limited. (n.d.). Entyvio prescribing information. Retrieved from https://www.entyvio.com/
[2] Loftus, E. V., et al. (2017). Vedolizumab versus azathioprine or placebo in patients with Crohn's disease: the GEMINI I randomised trial. The Lancet, 389(10071), 791-800.
[3] Sandborn, W. J., et al. (2017). Safety and efficacy of vedolizumab in patients with Crohn’s disease: 52-week results from the GEMINI I study. Gastroenterology, 146(4), 763-773.
